Genovis

65 articles about Genovis

• Genovis Launches Immobilized SialEXO® for Efficient Biopharmaceutical Sample Preparation

  12/11/2019

   Genovis continues to expand their product line of SmartEnzymes for Glycobiology by launching Immobilized SialEXO at the Antibody Engineering and Therapeutics conference in San Diego. Application data developed in collaboration with ProteinSimple, an industry leader within capillary electrophoresis, will be presented in a joint poster at the conference.

• Genovis launches SialEXO®23 to enhance glycan research

  5/28/2019

  Genovis expands its portfolio of glycan specific enzymes with the launch of SialEXO 23. A new member of the SialEXO family, SialEXO 23 is an enzyme for study of a specific type of sugar on biopharmaceuticals.

• Hansa Biopharma Divests its Equity Holding in Genovis

  4/15/2019

  Proceeds to be used to further expedite development of Company's pipeline

• Genovis Year-end Report January – December 2018

  2/26/2019

  Genovis has chosen to apply IFRS 16 in advance, as well as the simplification rule regarding short-term leases.

• Genovis Interim Report January – September 2018

  11/27/2018

  Genovis became certified to ISO 9001:2015 Quality certification means that the management system meets the requirements imposed by International Standard ISO 9001:2015. The certification covers product development, production and sales.

• Genovis certified to ISO 9001:2015

  11/8/2018

  Quality certification means that the management system meets the requirements imposed by International Standard ISO 9001:2015. The certification covers product development, production and sales. 

• Genovis launches FabRICATOR®-HPLC for automated antibody analysis

  9/19/2018

  Today Genovis is initiating sales of the FabRICATOR-HPLC column for quality assessment of antibodies in automated analytical systems.

• Genovis Half-Yearly Report January – June 2018

  8/28/2018

  The extremely strong growth at the beginning of the year continued during the second quarter: sales surged 48 percent compared with the previous year and totaled SEK 8.6 million (5.8).

• Genovis launches GlycOCATCH™ for purification of O-glycosylated proteins

  4/27/2018

  With the addition of GlycOCATCH, Genovis is expanding its already unique offering of products within the field of O-glycans and streangthens its position as an innovator in this market.

• Genovis Signs Distribution Agreement in India

  12/8/2017

  Genovis is continuing to expand in Asia and has signed a distribution agreement with Allianz Bioinnovation for the Indian market.

• Genovis Signs Distribution Agreement With Shanghai Titan Scientific Ltd.

  11/7/2017

  A growing number of companies in China are focusing on biopharma, at the same time that global pharmaceutical companies are locating their process development and production in the area.

• Genovis Signs Distribution Agreement With Chinese Beijing Zhongyuan Ltd.

  9/18/2017

• Genovis Expands Its Product Portfolio And Launches Three Products For Glycan Analysis

  5/30/2017

• Genovis Expands Its Product Portfolio And Launches FabALACTICA

  5/2/2017

• Genovis Initiates Sales Of GlyCLICK

  4/27/2017

• Genovis And Promega Corporation Sign Global License Agreement And Settle Litigation

  6/30/2016

• Genovis Launches GingisREX And Expands Product Portfolio

  4/14/2016

• Genovis Has Signed A Strategic Cooperation Agreement With Alphalyse Inc.

  3/17/2016

• Genovis Release: Year-End Report January-December 2015

  2/15/2016

• Genovis Launches New Enzyme Product

  12/3/2015